Mikhail Blagosklonny is an experienced educator and scientist. His area of specialization is cancer and aging. An oncology professor at New York’s Roswell Park Cancer Institute, he is known for his theory on TOR’s role in aging and cancer and the potential for treating it with rapamycin. Blagosklonny has published almost 300 articles in peer-reviewed publications and was editor-in-chief of Cell Cycle, Aging and Oncotarget, and Cancer Biology & Therapy’s associate editor. He’s on Cell Death & Differentiation’s editorial board.
A graduate of First Pavlov State Medical University of St. Petersburg, Blagosklonny has a PhD in Cardiology and Experimental Medicine and an M.D. in Internal Medicine. In 2002 he became a New York Medical College, Valhalla associate professor of medicine. He then became a senior scientist with Ordway Research Institute where he remained until 2009. Mikhail Blagosklonny was appointed a Roswell Park Cancer Institute professor of oncology. Part of what makes him such a good educator is his research and understanding of cancer, targeted cancer therapies to protect normal cells, anti-aging drugs and the mechanisms underlying aging.
His theories on the use of rapamycin to treat aging related issues have created growing interest in Mikhail Blagosklonny. His major point of emphasis is the role TOR plays in signaling what is going on in the body with aging and cancer in the body. He’s also a proponent of the use of the cancer drug rapamycin to treat ailments related to aging and improve and lengthen people’s lives. His work has helped to distinguish Blagosklonny as longevity research’s most passionate advocates for the use of rapamycin.
Cancer research is a core element of Blagosklonny’s mission. Mikhail Blagosklonny’s played a major role in some of the groundbreaking research being done in the field. He has helped many students, doctors and researchers to gain a greater understanding of cancer’s nature and has led to major advances in the diagnosis and treatment of the disease. His classes have provided students with a superior, comprehensive educational experience. Blagosklonny’s interests and research in molecular and cellular biology and their relationship to clinical investigations is legendary.
With the help of Mikhail Blagosklonny strategies like cellular senescence, cell cycle, signal transduction, and anticancer therapeutics which emphasize the creation of new anticancer treatments from the translation of basic science have grown in popularity. Blagosklonny has dedicated over 30 years of his life to the research and treatment of cancer and age related issues.